Ajanta Pharma Limited, a specialty pharmaceutical formulation company, has announced robust financial results for the second quarter of fiscal year 2026, demonstrating strong growth across key metrics.

Financial Highlights

The company reported impressive year-over-year growth in its Q2 FY 2026 performance:

The company experienced a mark-to-market forex loss of Rs. 41.00 cr. Excluding this impact, the adjusted EBITDA stood at Rs. 369.00 cr., reflecting a 9.00% growth with an EBITDA margin of 27.00%. Similarly, the adjusted PAT grew by 23.00%, with a margin of 22.00%.

Segment-wise Performance

Ajanta Pharma's business segments showed varied performance:

The company's branded generics business, which accounts for 72.00% of total revenue, grew by 8.00% overall. The US generics segment showed remarkable growth of 48.00%, while the Africa Institution business experienced a decline.

Market Performance

According to IQVIA MAT September 2025 data, Ajanta Pharma's India branded generic performance exceeded the Indian Pharmaceutical Market (IPM) growth by 32.00%. This growth was primarily driven by:

• Volume increase: Exceeded IPM by 115.00%
• New launches: Exceeded IPM by 39.00%

The company outperformed the IPM in key therapeutic areas:

R&D and Product Pipeline

Ajanta Pharma maintains a strong focus on research and development:

• R&D expenses for Q2 FY 2026: Rs. 63.00 cr. (5.00% of revenue)
• R&D expenses for H1 FY 2026: Rs. 119.00 cr. (5.00% of revenue)

The company's ANDA (Abbreviated New Drug Application) status as of H1 FY 2026:

• Total ANDAs commercialized: 50
• Awaiting approval with US FDA: 22
• Tentative approvals: 2

Dividend Announcement

The Board of Directors has approved a first interim dividend of Rs. 28.00 per share for the face value of Rs. 2.00 per share, amounting to Rs. 350.00 cr.

Future Outlook

Ajanta Pharma continues to focus on strategic priorities, including:

1. New product launches across markets
2. Gaining market share in existing products
3. Enhancing field force productivity
4. Expanding into new countries and therapies
5. Optimizing expenses through cost management and digitalization

With a strong product portfolio under development and registration, Ajanta Pharma is well-positioned for continued growth in the pharmaceutical market.

The company's performance demonstrates its resilience and ability to navigate challenging market conditions while maintaining a focus on growth and shareholder value.

Ajanta Pharma Limited has announced that its Board of Directors will convene on November 3, 2025, to deliberate on several key financial matters, including the declaration of the company's first interim dividend for the fiscal year ending March 31, 2026.

Key Points of the Announcement

• Board Meeting Date: November 3, 2025
• Agenda Items:
  • Consider declaring the first interim dividend for FY 2025-26
  • Review unaudited financial results for Q2 and H1 FY 2025-26
  • Potentially fix the record date for dividend payment

Dividend Considerations

The pharmaceutical company has informed the stock exchanges that if an interim dividend is declared, the Board will consider setting November 10, 2025, as the record date for determining shareholder eligibility.

Financial Review

In addition to the dividend deliberation, the Board meeting will focus on reviewing the company's financial performance. The agenda includes:

• Examination of unaudited financial results for the second quarter (Q2) of FY 2025-26
• Review of half-yearly (H1) financial results ending September 30, 2025

Regulatory Compliance

Ajanta Pharma's announcement aligns with regulatory requirements, as stated in their official communication:

"Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider: a. declaration of 1st interim dividend for the financial year ending 31st March 2026; and b. fixation of Monday, 10th November 2025 as the Record Date for the payment of interim dividend, if declared."

Investor Implications

Shareholders and potential investors should mark these dates:

Investors are advised to monitor the outcome of this board meeting, as it may impact the company's stock price and provide insights into Ajanta Pharma's financial health and shareholder return policies.

The company has requested the stock exchanges to disseminate this information to all concerned parties, ensuring transparency and compliance with market regulations.